With all due respect and I don't like to cross promote but, has a R.A.C. holder.
The drug Bisantrene has gone through some 40 Phase 2 trial's in the 80's and 90's.
The company first priority is the Acute Myeloid Leukaemia (A.M.L).
It has also gone through a phase 2 trial in breast cancer in the late 80's, with great result's, back then.
This study was done to 2020 standard's, has you are well aware technologies have improved since then.
Plenty of information on the company web site.
In relation to I.M.U., the company has fantastic set of drug's that, one day it will cure Gastric cancer and hopefully other cancer's as well.
To get to that stage it take's, 1 - Time, 2 - Money and 3 - Luck.
So, I have No doubt's in my Mind that I.M.U. will get their in due cause, that's why I invested in I.M.U. yesterday.
In relation to I.M.U. been undervalued, you are correct, but the general market are after 1 thing and that is raw data on the drug's and approval's.
I have a relative who work's for a very large Pharma company in Europe and he has said to me that from Phase 1 trial all the way to Phase 4 trial (Commercialisation of the Product), take's 7 to 10 year's.
So like management has stated today at the A.G.M. the next 12 Month, will be big for Imugene.
IMHO.
Regard's
Rossi70
IMU Price at posting:
12.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)